Literature DB >> 16111658

Stable inhibition of hepatitis B virus expression and replication by expressed siRNA.

Guang-Li Ren1, Xue-Fan Bai, Yan Zhang, Hong-Mei Chen, Chang-Xing Huang, Ping-Zhong Wang, Guang-Yu Li, Ying Zhang, Jian-Qi Lian.   

Abstract

RNA interference might be an efficient antiviral therapy for some obstinate illness. Here, we studied the effects of hepatitis B virus (HBV)-specific 21-nt small interfering RNAs (siRNA) on HBV gene expression and replication in 2.2.15 cells. Seven vectors expressing specific hairpin siRNA driven by the RNA polymerase II-promoter were constructed and transfected into 2.2.15 cells. In the cell strain that can stably express functional siRNA, the HBV surface antigen (HBsAg) and the HBV e antigen (HBeAg) secretion into culture media was inhibited by 86% and 91%, respectively, as shown by an enzyme-linked immunosorbent assay. Immunofluorescence and Western blot indicated similar results. HBV DNA was markedly restrained by 3.28-fold, as assessed by the fluorescent quantitation PCR. Moreover, the HBV mRNA was significantly reduced by 80% based on semiquantitative RT-PCR. In conclusion, the specific siRNA can knock down the HBV gene expression and replication in vitro, and the silence effects have no relationship with interferon response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16111658     DOI: 10.1016/j.bbrc.2005.07.170

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis.

Authors:  Jason Lamontagne; Mark Pinkerton; Timothy M Block; Xuanyong Lu
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

2.  A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice.

Authors:  Ye Zhang; Wen-Jing Su; Jue Wang; Xue-Fan Bai; Chang-Xing Huang; Jian-Qi Lian
Journal:  Viral Immunol       Date:  2014-09-11       Impact factor: 2.257

3.  Involvement of the Akt/NF-κB pathways in the HTNV-mediated increase of IL-6, CCL5, ICAM-1, and VCAM-1 in HUVECs.

Authors:  Haitao Yu; Wei Jiang; Hong Du; Yuan Xing; Guangzhen Bai; Ye Zhang; Yu Li; Hong Jiang; Ying Zhang; Jiuping Wang; Pingzhong Wang; Xuefan Bai
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

4.  Small interfering RNA targeting for infected-cell polypeptide 4 inhibits herpes simplex virus type 1 replication in retinal pigment epithelial cells.

Authors:  Fang Duan; Shiming Ni; Yuhong Nie; Qiang Huang; Kaili Wu
Journal:  Clin Exp Ophthalmol       Date:  2011-10-20       Impact factor: 4.207

5.  Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity.

Authors:  Yan Mu; Xiao-He Ren; Di Han; Ying-Ying Guan; Pei-Ling Liu; Si-Xue Cheng; Hong Liu
Journal:  Pharmaceutics       Date:  2022-07-09       Impact factor: 6.525

6.  Changes in innate and permissive immune responses after hbv transgenic mouse vaccination and long-term-siRNA treatment [corrected].

Authors:  Guang-Li Ren; Guang-Yu Huang; Hong Zheng; Ying Fang; Heng-Hao Ma; Man-Chun Xu; Hong-Bin Zhang; Wei-Yun Zhang; Ya-Gang Zhao; Da-Yong Sun; Wen-Kui Hu; Jian Liu
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

Review 7.  RNAi for treating hepatitis B viral infection.

Authors:  Yong Chen; Guofeng Cheng; Ram I Mahato
Journal:  Pharm Res       Date:  2007-12-12       Impact factor: 4.200

8.  Specific interference shRNA-expressing plasmids inhibit Hantaan virus infection in vitro and in vivo.

Authors:  Yuan-yuan Liu; Liang-jun Chen; Yan Zhong; Meng-xin Shen; Nian Ma; Bing-yu Liu; Fan Luo; Wei Hou; Zhan-qiu Yang; Hai-rong Xiong
Journal:  Acta Pharmacol Sin       Date:  2016-03-14       Impact factor: 6.150

9.  Inhibition of herpes simplex virus type 1 by small interfering RNA.

Authors:  Y Q Zhang; W Lai; H Li; G Li
Journal:  Clin Exp Dermatol       Date:  2007-11-02       Impact factor: 3.470

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.